Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer

NCT07820358 is registered in ClinicalTrials.gov with The Methodist Hospital Research Institute as lead sponsor.

NCT NCT07820358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07820358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Semaglutide, Weight Loss, And Intrauterine Therapy For Fertility-Sparing And Conservative Treatment For Endometrial Atypical Hyperplasia And Early-Stage, Grade 1 Endometrioid Endometrial Cancer
Lead sponsor
The Methodist Hospital Research Institute
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
December 31, 2031
Enrollment
48 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial atypical hyperplasia, endometrial atypical hyperplasia/endometrioid intraepithelial neoplasia, endometrial cancer, endometrial cancer stage i, fertility-sparing treatment (fst), obesity & overweight